Dopamine Homeostasis, Vesicles & Neurodegeneration

多巴胺稳态,囊泡

基本信息

项目摘要

DESCRIPTION: (Verbatim from the Applicant's Abstract) Parkinson's disease is a debilitating motor impairment disorder due to loss of nigral dopamine neurons. Mitochondrial defects in PD patients implicate energy impairment and metabolic stress as potential factors in its etiology. Moreover, DA oxidation products may add to the oxidative burden within DA neurons which, coupled with a persistent metabolic stress, may lead to neurodegeneration. Epidemiological studies link PD with environmental exposure to substances such as pesticides. - Many pesticides are mitochondrial inhibitors. A potential form of protection against mitochondrial toxins (i.e., MPP+) may be their sequestration into synaptic vesicles of DA neurons. The goal of this project is to gain an understanding of the role of vesicles, the vesicular monoamine transporter (VMAT2) and DA in modulating neurodegeneration produced by mitochondrial toxins. One hypothesis is that the actions of mitochondrial toxins can be modulated in contrasting ways depending on whether the toxins are sequestered into vesicles. If sequestered, toxin exposure could be abrogated. In contrast, disruption of vesicular function toxin could lead to disturbed DA homeostasis and enhanced toxicity since it would remove the toxin from interaction with mitochondria. In Aim 1 several mitochondrial toxins will be examined for their ability to interfere with vesicle function (i.e. to inhibit DA uptake into isolated rat membrane vesicles). In aim 2, rat mesencephalic cultures or rat striata will be exposed to mitochondrial toxins following VMAT2 inhibition to determine if toxicity is modified. To examine the hypothesis that disturbed DA homeostasis contributes to degeneration produced by metabolic stress, two approaches will be used. First, DA will be depleted prior to exposure of culture or rat striata to a mitochondrial inhibitor. Second, vesicle contents (DA) will be released into the cytosol after exposure to the mitochondrial toxin to examine if augmented disruption of DA homeostasis during the metabolic stress enhances toxicity. Additionally, the hypothesis that substances that are not themselves mitochondrial inhibitors, but can disrupt DA storage in vesicles may amplify damage during episodes of metabolic stress will be examined in Aim 3. In aim 4 the hypothesis that early events such as oxidative stress leads to loss of vesicle function, disruption of DA homeostasis and exacerbation of neurodegeneration produced by toxins will be investigated. Isolated vesicles will be tested for their sensitivity to oxidizing and reducing conditions. Results from these studies will provide novel and relevant information as to the contribution of VMAT2 containing vesicles in neuroprotection as well as in neurodegeneration of DA neurons during metabolic stress.
描述:(摘自申请人摘要)帕金森病是一种疾病

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Patricia K Sonsalla其他文献

Patricia K Sonsalla的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Patricia K Sonsalla', 18)}}的其他基金

Angiotensin and Neurodegeneration
血管紧张素和神经变性
  • 批准号:
    7586312
  • 财政年份:
    2008
  • 资助金额:
    $ 30.35万
  • 项目类别:
Developing and Improving Institutional Animal Resources
开发和改善机构动物资源
  • 批准号:
    6909640
  • 财政年份:
    2005
  • 资助金额:
    $ 30.35万
  • 项目类别:
Adenosine, Glutamate and Neurodegeneration
腺苷、谷氨酸和神经变性
  • 批准号:
    7071273
  • 财政年份:
    2005
  • 资助金额:
    $ 30.35万
  • 项目类别:
Adenosine, Glutamate and Neurodegeneration
腺苷、谷氨酸和神经变性
  • 批准号:
    7418642
  • 财政年份:
    2005
  • 资助金额:
    $ 30.35万
  • 项目类别:
Adenosine, Glutamate and Neurodegeneration
腺苷、谷氨酸和神经变性
  • 批准号:
    6963568
  • 财政年份:
    2005
  • 资助金额:
    $ 30.35万
  • 项目类别:
Adenosine, Glutamate and Neurodegeneration
腺苷、谷氨酸和神经变性
  • 批准号:
    7167839
  • 财政年份:
    2005
  • 资助金额:
    $ 30.35万
  • 项目类别:
Adenosine, Glutamate and Neurodegeneration
腺苷、谷氨酸和神经变性
  • 批准号:
    7248636
  • 财政年份:
    2005
  • 资助金额:
    $ 30.35万
  • 项目类别:
Dopamine Homeostasis, Vesicles & Neurodegeneration
多巴胺稳态,囊泡
  • 批准号:
    6320413
  • 财政年份:
    2001
  • 资助金额:
    $ 30.35万
  • 项目类别:
Dopamine Homeostasis, Vesicles & Neurodegeneration
多巴胺稳态,囊泡
  • 批准号:
    6540439
  • 财政年份:
    2001
  • 资助金额:
    $ 30.35万
  • 项目类别:
Dopamine Homeostasis, Vesicles & Neurodegeneration
多巴胺稳态,囊泡
  • 批准号:
    6718954
  • 财政年份:
    2001
  • 资助金额:
    $ 30.35万
  • 项目类别:

相似海外基金

Relationship between neurotoxicity and the chemical structures of amphetamines
安非他明的神经毒性与化学结构的关系
  • 批准号:
    25860103
  • 财政年份:
    2013
  • 资助金额:
    $ 30.35万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Search for protein expression in amphetamines treated mouse heart : Challenge to the diagnosis for the sudden death of amphetamines abusers
寻找安非他明治疗小鼠心脏中的蛋白质表达:对安非他明滥用者猝死诊断的挑战
  • 批准号:
    22659138
  • 财政年份:
    2010
  • 资助金额:
    $ 30.35万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
  • 批准号:
    8312648
  • 财政年份:
    2010
  • 资助金额:
    $ 30.35万
  • 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
  • 批准号:
    8531900
  • 财政年份:
    2010
  • 资助金额:
    $ 30.35万
  • 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
  • 批准号:
    8715749
  • 财政年份:
    2010
  • 资助金额:
    $ 30.35万
  • 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
  • 批准号:
    8144930
  • 财政年份:
    2010
  • 资助金额:
    $ 30.35万
  • 项目类别:
Translational Genetics and Dopamine Signaling in Sensitivity to Amphetamines
安非他明敏感性中的转化遗传学和多巴胺信号传导
  • 批准号:
    7675601
  • 财政年份:
    2009
  • 资助金额:
    $ 30.35万
  • 项目类别:
Simultaneous determination of ephedrines, amphetamines, cocaine, cocaine metabolites, and opiates and interaction in the rat
大鼠体内麻黄碱、安非他明、可卡因、可卡因代谢物和阿片类药物的同时测定及其相互作用
  • 批准号:
    17590585
  • 财政年份:
    2005
  • 资助金额:
    $ 30.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study for practical use of two chiral analyses of amphetamines by gas chromatography-mass spectrometry
气相色谱-质谱法对苯丙胺两种手性分析的实用化研究
  • 批准号:
    17590588
  • 财政年份:
    2005
  • 资助金额:
    $ 30.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clinical Pharmacology of 3,4-Methylenedioxy Amphetamines
3,4-亚甲二氧基安非他明的临床药理学
  • 批准号:
    6870119
  • 财政年份:
    2004
  • 资助金额:
    $ 30.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了